151. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
- Author
-
Hornik CP, Herring AH, Benjamin DK Jr, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, and Smith PB
- Subjects
- Anti-Bacterial Agents administration & dosage, Cilastatin administration & dosage, Cilastatin, Imipenem Drug Combination, Cohort Studies, Drug Combinations, Humans, Imipenem administration & dosage, Incidence, Infant, Intensive Care, Neonatal, Meropenem, Retrospective Studies, Seizures epidemiology, Seizures pathology, Survival Analysis, Thienamycins administration & dosage, Anti-Bacterial Agents adverse effects, Cilastatin adverse effects, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Imipenem adverse effects, Thienamycins adverse effects
- Abstract
Background: Carbapenems are commonly used in hospitalized infants despite a lack of complete safety data and associations with seizures in older children. We compared the incidence of adverse events in hospitalized infants receiving meropenem versus imipenem/cilastatin., Methods: We conducted a retrospective cohort study of 5566 infants treated with meropenem or imipenem/cilastatin in neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2010. Multivariable conditional logistic regression was performed to evaluate the association between carbapenem therapy and adverse events, controlling for infant factors and severity of illness., Results: Adverse events were more common with use of meropenem compared with imipenem/cilastatin (62.8/1000 infant days versus 40.7/1000 infant days, P < 0.001). There was no difference in seizures with meropenem versus imipenem/cilastatin (adjusted odds ratio 0.96; 95% confidence interval: 0.68, 1.32). The incidence of death, as well as the combined outcome of death or seizure, was lower with meropenem use-odds ratio 0.68 (0.50, 0.88) and odds ratio 0.77 (0.62, 0.95), respectively., Conclusion: In this cohort of infants, meropenem was associated with more frequent but less severe adverse events when compared with imipenem/cilastatin.
- Published
- 2013
- Full Text
- View/download PDF